ABSTRACT BACKGROUND Heart failure (HF) is associated with excess morbidity and mortality for which noncardiac causes are
Although certain characteristics and risk factors may differ between those who develop HF and those who do not, such as older age, obesity, smoking, diabetes, larger anterior infarcts (5) , and delayed reperfusion (6) , these are largely known and can be controlled for in the analysis. Therefore, comparing these 2 groups may provide more information on the impact of heart failure on the occurrence of subsequent cancer.
In this study, we evaluated the association between HF and subsequent cancer risk among first MI survivors. H e a r t f a i l u r e . Clinical diagnoses of HF were reviewed and validated according to the Framingham criteria. These criteria require the presence of at least 2 major criteria, or 1 major criterion in addition to 2 minor criteria, to confirm HF (10) . The type of HF was defined according to echocardiographically measured ejection fraction (EF) as heart failure with reduced ejection fraction (HFrEF) (EF <50%) or heart failure with preserved ejection fraction (HFpEF) (EF $50%) (11) . EF was measured as previously described (12) . The EF measurement that was closest to the HF diagnosis (applying a pre-defined maximum period of 60 days) was recorded for each participant.
METHODS
C a n c e r . Cancer types were classified by anatomic and system primary involvement (13); nonmelanoma skin cancers were excluded from the study. The date of first cancer diagnosis was used as the diagnosis date.
D e a t h . Death was ascertained using multiple sources including autopsy reports, death certificates filed in Olmsted County, obituary notices, and electronic death certificates obtained from the Section of Vital Statistics, Minnesota Department of Health, as previously described (14) . The study includes patients from Olmsted County, Minnesota, after MI. Patients with and without post-MI heart failure were compared. HF ¼ heart failure; MI ¼ myocardial infarction. Incidence density rates for cancer diagnosis (1,000 person-years) were 33.7 for patients with HF and 15.6 for patients without HF (p ¼ 0.002) ( Table 2) .
Types of cancer were classified according to system involvement. Among patients with HF, the most common types of cancer were respiratory (n ¼ 8; 29% of cancer diagnoses), digestive (n ¼ 8; 29%), and hematologic (n ¼ 4; 14%). The most common cancers among patients without HF were male reproductive (n ¼ 15; 21%), respiratory (n ¼ 12; 17%), digestive (n ¼ 10; 14%), and female breast (n ¼ 8; 11%) ( Table 3) .
The difference in cancer system involvement between groups was not statistically significant (Fisher exact test p ¼ 0.087).
The cumulative incidence of cancer among patients with and without HF 30 days after MI is shown in the Central Illustration. The incidence of cancer between groups was similar initially, but diverged after 1.5 years of follow-up, with higher rates of cancer among the HF patients. Including all HF diagnoses after MI, the unadjusted and adjusted associations between HF and cancer in the entire cohort and by sex and age subgroups are shown in Cancer involved multiple organ systems, without significant differences between the groups regarding system involvement. The increased incidence in cancer began approximately 1.5 years after HF diagnosis. Both HF and cancer were independently associated with increased mortality after MI.
We previously reported an increased risk of cancer among HF patients as compared with community controls (3). In the present, study, the HF and non-HF patients shared many of the risk factors, diagnostic procedures, and medications because all patients were survivors of MI. Therefore, the present study supports the previous finding that HF is associated with an increased risk of cancer. In an exploratory analysis, we observed a seemingly more prominent risk of cancer in patients with reduced EF. This observation should be interpreted Values are rate per 1,000 person-years or hazard ratio (95% confidence interval). *Adjusted for age, sex, and Charlson comorbidity index (the sex-specific estimates are adjusted for age and comorbidity, whereas the age-specific estimates are adjusted for sex and comorbidity). †Further adjusted for hypertension, smoking, BMI, anterior MI, peak cTnT, Killip class, reperfusion/revascularization, and treatment with aspirin at hospital discharge. ‡Adjusted for sex and Charlson comorbidity index (the age-specific estimates are adjusted for comorbidity). §Further adjusted for hypertension, smoking, BMI, anterior MI, peak cTnT, Killip class, reperfusion/revascularization, and treatment with aspirin at hospital discharge.
Abbreviations as in Table 1 . as hypothesis generating, rather than hypothesis testing. The pathways leading to altered healing and reduced EF after MI are complex, and HF after MI was reported to be associated with altered immunity, highlighting the role of the monocyte system (24).
These or similar mechanisms for repair of damaged tissue might also be associated with an increased risk of cancer.
Cancer constitutes an enormous burden to society Cumulative incidence of cancer according to heart failure (HF) status 30 days after incident myocardial infarction (MI), with death considered a competing event.
Hasin et al. Heart Failure After MI Increases Cancer Risk J U L Y 1 9 , 2 0 1 6 : 2 6 5 -7 1 findings were statistically significant, the small sample size and number of events are a potential limitation, and confirmation with a larger cohort may be warranted.
CONCLUSIONS
Patients who develop HF after MI have an increased risk of cancer. The risk is increased irrespective of age and sex, and confers an additional risk of death. 
